ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2022
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05374564 (Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- [Nuclear medicine-necessity and opportunities in modern cardiology].Innere Medizin (Heidelberg, Germany) · 2026Review
- Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis.European heart journal. Imaging methods and practice · 2026Article
- Head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic parameters and detection of cardiac amyloidosis with hybridEuropean journal of nuclear medicine and molecular imaging · 2026Observational
- Biomarker-Imaging Dissociation in Wild-Type Cardiac Amyloidosis after Treatment with Patisiran.Arquivos brasileiros de cardiologia · 2026Article
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- Enhanced diagnostic and prognostic assessment of cardiac amyloidosis using combinedEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Positron emission tomography in cardiac amyloidosis: current evidence and future directions.Heart failure reviews · 2025Review
- Recent Advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis.Current cardiology reports · 2024Review
- Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2022: positron emission tomography, computed tomography, and magnetic resonance.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Review
- The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2023Article
- Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis.Biology · 2022Review
- Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Advanced Imaging in Cardiac Amyloidosis.Biomedicines · 2022Review
- Editorial:Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Positron emission tomography for cardiac amyloidosis: Timing matters!Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBone-tracer scintigraphy has an established role in diagnosis of cardiac amyloidosis (CA) as it detects transthyretin amyloidosis (ATTR). Positron emission tomography (PET) with amyloid tracers has shown high sensitivity for detection of both ATTR and light-chain (AL) CA. We aimed to investigate the accuracy of
methodsWe enrolled patients with CA or non-amyloid heart failure (NA-HF), who underwent cardiac
resultsWe included 17 patients (12 with CA, 5 with NA-HF). PET/MRI was conducted in 13 patients, while PET/CT was conducted in 4. LGE was detected in 8 of 9 CA patients. Global relaxation time and ECV were higher in CA (1448 vs. 1326, P = 0.02 and 58.9 vs. 33.7%, P = 0.006, respectively). Positive PET studies were demonstrated in 2 of 12 patients with CA (AL and ATTR). Maximal and mean SUV did not differ between groups (2.21 vs. 1.69, P = 0.18 and 1.73 vs. 1.30, P = 0.13).
conclusionAlthough protein-independent binding is supported by our results, the diagnostic yield of PET was low. We demonstrate here for the first time the low sensitivity of PET for CA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.